Stock Analysis, Dividends, Split History
ITCI / Intra-Cellular Therapies Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||1,160.38|
|Enterprise Value ($M)||1,090.62|
|Book Value ($M)||390.39|
|Book Value / Share||7.14|
|Price / Book||3.06|
|NCAV / Share||7.09|
|Price / NCAV||3.08|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1567514|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by Intra-Cellular Therapies Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Related News Stories
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)
Good morning, ladies and gentlemen and welcome to the Intra-Cellular Therapies Second Quarter 2018 earnings conference call. [Operator Instructions].
One candidate is at Phase 2, and the results are expected in first half of 2019. (205-3)
as of ET